




Detect lymphoma earlier than ever before.

IDEXX Cancer Dx™ testing clinical reference guide.

IDEXX



Canine cancer is incredibly common.




Approximately 1 in 4 dogs in the U.S. will be diagnosed with cancer in their lifetime.¹



Cancer is the leading cause of death in adult dogs.²

For many cancers, patients aren't diagnosed until the later stages and clinical signs are present. These types of situations often lead to poorer outcomes and lower survival rates.



Lymphoma is one of the most common cancers encountered in dogs, comprising up to 24% of new diagnoses.³

Clinical signs associated with canine lymphoma:³

- + Local or generalized lymphadenopathy
- + Skin masses/ulcers
- + Gastrointestinal mass
- + Increased thirst/urination with high calcium
- + Moderate to marked lymphocytosis
- + Bilateral uveitis
- + Fever of unknown origin
- + Cytopenias

Cancer risk in dogs is greatly shaped by two factors: age and breed.

Studies show that the risk of cancer increases with age.⁴



The average age of dogs diagnosed with cancer.⁴

Cancer screenings are recommended for all dogs age 7 or older as well as dogs age 4 and older from these breeds:

- + Beagle
- + Bernese mountain dog
- + Boston terrier
- + Boxer
- + Bullmastiff
- + Chinese pug
- + Doberman pinscher
- + English bulldog
- + Flat-coated retriever
- + French bulldog
- + German shepherd
- + Golden retriever
- + Irish wolfhound
- + Labrador retriever
- + Miniature schnauzer
- + Pembroke Welsh corgi
- + Rhodesian ridgeback
- + Rottweiler
- + Scottish deerhound
- + Scottish terrier
- + Shar-pei
- + Siberian husky
- + Weimaraner



Decrease the possibility of illness going undetected by expanding your preventive care offering.

Preventive care allows veterinarians to catch health issues earlier and help pets live healthy lives. With comprehensive diagnostics from IDEXX, you can get deeper medical insight into your patients' health. But even with comprehensive diagnostics, such as a CBC, chemistry profile, and urinalysis, cancer can still go undetected.

When it comes to cancer detection, the diagnosis often comes too late in the game. Until now, there has been no easy, affordable screening test that could be integrated into a wellness offering.



IDEXX Cancer Dx testing.

Accurate, affordable, early detection of lymphoma.

Help detect cancer as an additional component of your IDEXX Preventive Care diagnostics for at-risk dogs.*


What is IDEXX Cancer Dx testing?

IDEXX Cancer Dx™ testing is a groundbreaking diagnostic using multiple innovative, proprietary technologies to accurately detect circulating biomarkers specific for canine lymphoma. In many cases, a lymphoma phenotype is provided with high confidence, guiding prognosis and treatment plans.


Specimen requirements.

2 mL of serum and 1 mL of EDTA whole blood (LTT) when run as a standalone, add-on, or in a profile. When run in a profile with chemistry and CBC, IDEXX Cancer Dx testing is run using a portion of the 1 mL whole blood/2 mL serum specimen required for standard biochemistry and hematology testing, not a separate pair of tubes.

*At-risk dogs include all dogs ≥ 7 years old and high-risk breeds ≥ 4 years old.



In an internal validation study, IDEXX Cancer Dx testing identified 79% of dogs with lymphoma with 99% specificity against healthy controls and dogs with inflammatory diseases/other cancers.⁵



Why is cancer screening important?

There is a shifting focus in oncology to early detection of cancers to provide more time for planning and a larger scope of opportunities to treat the disease. Diagnosing lymphoma before it can cause illness in a dog has a great potential to improve outcomes.




Using IDEXX Cancer Dx in healthy dogs.

How does IDEXX Cancer Dx testing compare to other cancer screening strategies?

IDEXX Cancer Dx™ testing demonstrates performance that is comparable to, if not superior to, the current standards widely and consistently used in human cancer screening diagnostics today.⁶⁻⁷ IDEXX Cancer Dx testing also provides a lymphoma-specific result with additional characterization in many cases.

Metric	IDEXX Cancer Dx testing	Mammography ⁶	Colonoscopy ⁷
Sensitivity	79%*	65%–94%	75%–95%
Specificity	99%*	50%–98%	89%–94%

IDEXX Cancer Dx™ testing: Interpreting results for clinically ill dogs



Using IDEXX Cancer Dx in sick dogs.

Where does IDEXX Cancer Dx testing fit into the diagnostic workup of a patient suspected to have lymphoma?

Metric	IDEXX Cancer Dx testing	Cytology ⁸	Lymphoma PCR (PARR) ⁹⁻¹¹
Sensitivity	79%	92.6%	75%–92%
Specificity	99%	89.4%	94%–98.7%
Turnaround time [§]	2–3 days	1–5 days	10–14 days
Specimen	Serum/blood	Cells from lesion	Cells from lesion
Cost	\$	\$\$	\$\$\$

Where does IDEXX Cancer Dx testing fit into the available options for phenotyping of lymphoma?

Metric	IDEXX Cancer Dx testing	Lymphoma PCR (PARR) ¹²⁻¹³	Flow cytometry ¹³
B-cell specificity	91.3%	67%–89%	100%
T-cell specificity	98.8%	64%–100%	98%
Specimen	Serum/blood	Cells from lesion	Cells from lesion
Special handling?	No	No	Yes
Cost	\$	\$\$\$	\$\$\$

IDEXX Cancer Dx™ testing: Interpreting results for clinically well dogs

Not consistent with lymphoma

Result supports absence of detectable lymphoma; evaluate patient at next planned wellness examination*

Consistent with lymphoma

Evaluate full history, physical examination, and blood work

Further evaluation may be considered to confirm presence of disease, including the following:

- + Aspirates or biopsy of lymph nodes/organs
- + Diagnostic imaging (chest radiographs and abdominal ultrasound)
- + Flow cytometry of blood in cases of lymphocytosis

If lymphoma is not detected, perform recheck physical examination in 8–12 weeks (sooner if new symptoms arise)

*American Animal Hospital Association (AAHA) recommends wellness examinations every 6 months in senior dogs and yearly in all other dogs.¹

Reference

1. Creevy KE, Grady J, Little SE, et al. 2019 AAHA Canine Life Stage Guidelines. *J Am Anim Hosp Assoc.* 2019;55(6):267–290. doi:10.5326/JAAHA-MS-6999

Get the support you need when there's no time to waste.

Diagnosing cancer can be difficult, but the expanded cancer offerings at IDEXX Reference Laboratories can help.

The cancer diagnostics test and service menu at IDEXX Reference Laboratories can help identify cancer, understand personalized genetic markers, and determine diagnostics for therapy management and monitoring.




Personalized guidance from diagnosis to treatment.

Get the support that you need from the largest global network of veterinary pathologists and medical consultants at IDEXX Reference Laboratories:

- + Clinical support for routine and complex pathology cases
- + Easy access to your case's pathologist by phone and email, and consistency with a dedicated pathologist from start to finish
- + Education on when and which diagnostics are best for personalized medicine
- + Evaluation of surgical margins
- + Internal case review and collaboration
- + Comments about biological behavior and etiology
- + Cytology interpretation from a board-certified clinical pathologist in 2 hours or less, 24/7/365, with IDEXX Digital Cytology™*

*Requires the in-house IDEXX Digital Cytology™ instrument.



Expand your pathology insights with VetConnect PLUS.

Everything you need for faster, effective clinical decisions all in one place:

- + High-resolution digital images of your cytology and biopsy cases included at no charge, exclusively with VetConnect® PLUS
- + Access to each patient's comprehensive diagnostic information (CBC, chemistry profile, urinalysis, digital radiography) in one place for a holistic view in VetConnect PLUS



Our comprehensive diagnostic portfolio gives you clarity.

The cancer diagnostics test and service menu gives you the answers you need, when you need them:

Cancer identification

- + IDEXX Cancer Dx™ testing
- + Priority Cytology
- + Priority Biopsy
- + Bone Marrow Cytology and Biopsy with Microscopic Description

Cancer characterization

- + Mast Cell Tumor Prognostic Panel
- + Immunocytochemical Staining, as recommended by pathology
- + Immunohistochemistry, as recommended by pathology
- + Lymphoma PCR, includes the PARR assay for clonality

Chemotherapy patient monitoring

- + Cancer Baseline Profile with Urinalysis
- + Cancer Baseline Profile and SediVue Dx® Urinalysis†
- + Chemotherapy Recheck Profile
- + Chemotherapy Recheck Profile with Urinalysis

†Urinalysis is performed on the SediVue Dx® Urine Sediment Analyzer.



References

1. What are the most common types of cancers in dogs? How many dogs typically get cancer? Veterinary Cancer Society; 2021. Accessed March 21, 2025. www.vetcancersociety.org/pet-owners/faqs
2. Fleming JM, Creevy KE, Promislow DE. Mortality in North American dogs from 1984 to 2004: an investigation into age-, size-, and breed-related causes of death. *J Vet Intern Med.* 2011;25(2):187–198. doi:10.1111/j.1939-1676.2011.0695.x
3. Vail DM, Pinkerton M, Young KM. Hematopoietic tumors. In: Vail DM, Thamm DH, Liptak JM, eds. *Withrow & MacEwen's Small Animal Clinical Oncology*. 6th ed. Saunders; 2020:688–772. doi:10.1016/B978-0-323-59496-7.00033-5
4. Rafalko JM, Kruglyak KM, McCleary-Wheeler AL, et al. Age at cancer diagnosis by breed, weight, sex, and cancer type in a cohort of more than 3,000 dogs: determining the optimal age to initiate cancer screening in canine patients. *PLoS One.* 2023;18(2):e0280795. doi:10.1371/journal.pone.0280795
5. Data on file at IDEXX Laboratories, Inc. Westbrook, Maine USA: Data based on testing performed at IDEXX Reference Laboratories in North America between November 1, 2024, and December 6, 2024. *Analysis Report: IDEXX Cancer Dx Validation, 100282 [008_CancerDx-Validation-Report-2.Rmd]*.
6. Tadesse GF, Tegaw EM, Abdisa EK. Diagnostic performance of mammography and ultrasound in breast cancer: a systematic review and meta-analysis. *J Ultrasound.* 2023;26(2):355–367. doi:10.1007/s40477-022-00755-3
7. Lin JS, Perdue LA, Henrikson NB, Bean SI, Blasi PR. Screening for colorectal cancer: updated evidence report and systematic review for the US Preventive Services Task Force. *JAMA.* 2021;325(19):1978–1998. doi:10.1001/jama.2021.4417
8. Martini V, Marano G, Aresu L, et al. Performance of lymph node cytopathology in diagnosis and characterization of lymphoma in dogs. *J Vet Intern Med.* 2022;36(1):204–214. doi:10.1111/jvim.16326
9. Avery A. Molecular diagnostics of hematologic malignancies. *Top Companion Anim Med.* 2009;24(3):144–150. doi:10.1053/j.tcam.2009.03.005
10. Frequently asked questions. Colorado State University Clinical Hematopathology Laboratory. Accessed March 21, 2025. www.vetmedbiosci.colostate.edu/chl/faqs
11. Waugh EM, Gallagher A, Haining H, et al. Optimisation and validation of a PCR for antigen receptor rearrangement (PARR) assay to detect clonality in canine lymphoid malignancies. *Vet Immunol Immunopathol.* 2016;182:115–124. doi:10.1016/j.vetimm.2016.10.008
12. Ehrhart EJ, Wong S, Richter K, et al. Polymerase chain reaction for antigen receptor rearrangement: benchmarking performance of a lymphoid clonality assay in diverse canine sample types. *J Vet Intern Med.* 2019;33(3):1392–1402. doi:10.1111/jvim.15485
13. Thalheim L, Williams LE, Borst LB, Fogle JE, Suter SE. Lymphoma immunophenotype of dogs determined by immunohistochemistry, flow cytometry, and polymerase chain reaction for antigen receptor rearrangements. *J Vet Intern Med.* 2013;27(6):1509–1516. doi:10.1111/jvim.12185

IDEXX

> idexx.com/cancerdx

IDEXX
One IDEXX Drive
Westbrook, ME 04092
United States

© 2025 IDEXX Laboratories, Inc. All rights reserved. • 09-2691876-02
All ®/TM marks are owned by IDEXX Laboratories, Inc. or its affiliates
in the United States and/or other countries. The IDEXX Privacy Policy
is available at idexx.com.